Heitmann, J. S., Walz, J. S., Pflügler, M., Kauer, J., Schlenk, R. F., Jung, G., & Salih, H. R. (2020). Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma. BMJ open, 10(10), . https://doi.org/10.1136/bmjopen-2020-039639
Chicago-Zitierstil (17. Ausg.)Heitmann, Jonas S., Juliane S. Walz, Martin Pflügler, Joseph Kauer, Richard Friedrich Schlenk, Gundram Jung, und Helmut R. Salih. "Protocol of a Prospective, Multicentre Phase I Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration-resistant Prostate Carcinoma." BMJ Open 10, no. 10 (2020). https://doi.org/10.1136/bmjopen-2020-039639.
MLA-Zitierstil (9. Ausg.)Heitmann, Jonas S., et al. "Protocol of a Prospective, Multicentre Phase I Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration-resistant Prostate Carcinoma." BMJ Open, vol. 10, no. 10, 2020, https://doi.org/10.1136/bmjopen-2020-039639.